SubjectWell is an audience engagement platform for healthcare that matches patients with chronic conditions to clinical trials and other new care options. It uses a direct-to-consumer approach and reports registering 250,000 new patients per month while saying it can engage the 96 percent of the population that has never participated in clinical research. SubjectWell now partners with 16 of the top 20 pharmaceutical companies and has expanded into oncology, recruiting for non-small cell lung cancer and breast cancer studies. Revenue has grown 800 percent over the past two years, and the company says it is poised to double revenue again in the next 12 months. The platform aims to accelerate clinical trial enrollment timelines, support cancer research, and increase awareness and engagement for post-approval treatments through new service offerings. SubjectWell plans to use its scale and media-channel patient aggregation to extend awareness initiatives and commercial support for pharmaceutical customers. SubjectWell operates a risk-free clinical trials marketplace that connects prospective patients with available clinical studies. The platform’s core product is a single marketplace to build awareness and increase participation in clinical research by matching patients to trials. SubjectWell uses a performance-based pricing model and is compensated only for patients who randomize into studies. The company says hundreds of studies are already recruiting through its marketplace. The recent funding will support international expansion beyond North America into Europe, South America, and the United Kingdom. SubjectWell is headquartered in Austin, Texas and aims to broaden its patient pool and accelerate study enrollment.

Total raised

$45M

Funding rounds

2

Latest round

Series B

Latest activity

Oct 2022